Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
GOVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.88 - $11.18
Previous CloseN/A
Volume281.82K
Average Volume (3M)660.61K
Market Cap
$14.12M
Enterprise Value$20.52M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.08
Next Earnings
May 01, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding13,839,478
10 Day Avg. Volume384,018
30 Day Avg. Volume660,611
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.03
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.99
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$11.70Price Target Upside1093.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
GeoVax Labs News
PremiumCompany Announcements
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Financial SupportGeoVax Labs received a significant Project NextGen (PNG) award from BARDA worth $443M, indicating strong financial support for advancing their vaccine trials.
Market PositionGeoVax Labs is focused on near-term progress with its GEO-CM04S1 Phase 2 trials, which could position the company as a new vaccine player in 2025.
Bears Say
Contract TerminationGeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
MRNA Vaccine ComparisonThe DSMB did not recommend continuing the mRNA vaccine arm, which failed the study’s predetermined primary endpoint of the T cell-based immune response rate.
---
Ownership Overview
1.49% Insiders
0.74% Mutual Funds
0.02% Other Institutional Investors
96.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GOVX FAQ
What was GeoVax Labs’s price range in the past 12 months?
GeoVax Labs lowest stock price was $0.88 and its highest was $11.18 in the past 12 months.
What is GeoVax Labs’s market cap?
GeoVax Labs’s market cap is $14.12M.
When is GeoVax Labs’s upcoming earnings report date?
GeoVax Labs’s upcoming earnings report date is May 01, 2025 which is in 5 days.
How were GeoVax Labs’s earnings last quarter?
GeoVax Labs released its earnings results on Mar 27, 2025. The company reported -$0.876 earnings per share for the quarter, missing the consensus estimate of -$0.802 by -$0.074.
Is GeoVax Labs overvalued?
According to Wall Street analysts GeoVax Labs’s price is currently Undervalued.
Does GeoVax Labs pay dividends?
GeoVax Labs does not currently pay dividends.
What is GeoVax Labs’s EPS estimate?
GeoVax Labs’s EPS estimate is -0.66.
How many shares outstanding does GeoVax Labs have?
GeoVax Labs has 13,839,478 shares outstanding.
What happened to GeoVax Labs’s price movement after its last earnings report?
GeoVax Labs reported an EPS of -$0.876 in its last earnings report, missing expectations of -$0.802. Following the earnings report the stock price went down -12.598%.
Which hedge fund is a major shareholder of GeoVax Labs?
Currently, no hedge funds are holding shares in GOVX
---
Company Description
GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
---
GOVX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While there were significant achievements such as the BARDA award and advancements in vaccine development, financial challenges and delays in clinical trials were also highlighted.Read More>---
GOVX Stock 12 Month Forecast
Average Price Target
$11.70
▲(1093.88% Upside)
Technical Analysis
Phio Pharmaceuticals
―
Moleculin Biotech
―
ABVC BioPharma, Inc.
―
Addex Therapeutics
―
Sensei Biotherapeutics
―
Best Analysts Covering GOVX
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-56.25%
reiterated a buy rating 12 days ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.25% per trade.
---